IMWG衰弱评分与复发难治多发性骨髓瘤患者健康相关生活质量的相关性
该多中心横断面研究纳入意大利和英国415例复发难治多发性骨髓瘤患者,按IMWG衰弱评分分为fit、intermediate-fit和frail三组,发现各组具有不同的健康相关生活质量特征,fit与frail组在躯体功能、疲乏、失眠和呼吸困难等方面差异显著。
要点
- IMWG衰弱评分可区分复发难治骨髓瘤患者不同的生活质量特征。
核心结论
- IMWG衰弱评分在复发难治多发性骨髓瘤中具有临床效用,有助于区分不同健康相关生活质量特征的患者组。
研究设计与样本
- 研究为前瞻性观察性研究的横断面分析,纳入意大利30家医院和英国伦敦1家医院年龄18岁及以上、接受过至少1线且不超过5线治疗的复发难治多发性骨髓瘤患者。
- 排除精神疾病或严重认知功能障碍者,以及研究入组前2周内出现任何3级及以上不良事件者。
主要发现
- 根据IMWG衰弱评分,200例(48%)为fit,112例(27%)为intermediate-fit,103例(25%)为frail。
关键数值与推荐
- IMWG衰弱评分包括Charlson共病指数、Katz日常生活活动能力和Lawton工具性日常生活活动能力。
- 患者报告结局测量采用EORTC QLQ-C30及其经验证的多发性骨髓瘤模块QLQ-MY20。
- 采用多变量线性回归模型评估衰弱组间健康相关生活质量评分的平均差异,并校正关键潜在混杂因素。
临床怎么用
- 在复发难治多发性骨髓瘤临床管理中,可采用IMWG衰弱评分识别具有不同健康相关生活质量特征的患者组。
- 对frail组患者应关注躯体功能下降、疲乏、失眠、呼吸困难和疼痛等高负担症状。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical management of patients with relapsed or refractory multiple myeloma is challenging and there is a paucity of tools to help clinicians make more informed decisions for the most suitable treatment options. We aimed to investigate the clinical utility of the International Myeloma Working Group (IMWG) frailty score in the setting of relapsed or refractory multiple myeloma, by examining its ability to capture different patient-reported health-related quality of life profiles. METHODS: We did a cross-sectional analysis of a prospective observational study of patients with relapsed or refractory multiple myeloma in Italy and the UK (30 hospitals across northern, central, and southern Italy, and one hospital in London, UK). Inclusion criteria were age 18 years or older and patients who had received at least one previous line of therapy and no more than five lines. Participants were excluded if they had a psychiatric disorder or major cognitive dysfunction, or any grade 3 or higher adverse event within 2 weeks before study entry. On study initiation, physicians had to assess frailty according to the IMWG criteria, which included the Charlson Comorbidity Index, the Katz Activity of Daily Living, and the Lawton Instrumental Activities of Daily Living. Patients were asked to complete patient-reported outcome measures, including the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) and its validated multiple myeloma module (QLQ-MY20). A multivariable linear regression model was used to assess the mean differences in health-related quality of life scores between frailty groups to account for key potential confounding factors. FINDINGS: Overall, between Nov 13, 2017, and Nov 15, 2021, 415 patients with relapsed or refractory multiple myeloma, with a median age of 69·8 years (IQR 62·8-75·2) were enrolled. The median time since diagnosis was 4·4 years (IQR 2·5-7·1) and most patients (351 [85%]) had received at least two previous lines of therapy. According to the IMWG frailty score, 200 (48%) were classified as fit, 112 (27%) were classified as intermediate-fit, and 103 (25%) patients were classified as frail. Each frailty group was associated with a distinct health-related quality of life profile, with most notable differences between fit and frail patients. The largest clinically meaningful adjusted differences between fit and frail patients by the EORTC QLQ-C30 questionnaire were observed for physical functioning (Δ=-19·0 [95% CI -25·6 to -12·5; p<0·0001), fatigue (Δ=16·7 [9·7 to 23·7]; p<0·0001), insomnia (Δ=13·4 [4·1 to 22·6]; p=0·0047), and dyspnoea (Δ=12·5 [4·6 to 20·4]; p=0·0021). The most prevalent clinically important symptom in the overall population was pain; however, its prevalence varied between IMWG frailty groups at 70·9% in frail patients, 55·9% in intermediate-fit patients, and 50·5% in fit patients. INTERPRETATION: Our findings show the clinical utility of the IMWG frailty score in the setting of relapsed or refractory multiple myeloma, in helping to distinguish between groups of patients with distinct health-related quality of life profiles. Further research is needed to examine the value of patient-reported outcome data in improving assessment of frailty in the setting of relapsed or refractory multiple myeloma. FUNDING: Fondazione GIMEMA Franco Mandelli Onlus and Amgen.
引用
- Efficace F, Gaidano G, Petrucci MT, et al. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. Lancet Healthy Longev. 2022. PMID: 36102777. doi:10.1016/S2666-7568(22)00172-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。